23:32 on June 17, 2022, Beijing time, Vaccinex Inc (VCNX.us) shares changed, and the share price rose 10.71% rapidly. As of press time, the stock was trading at US $1.24 per share, with a turnover of 95838 shares.Turnover rate0.22%, amplitude 15.18%.

Recent financial data show that the stock has an operating income of $0.00.Net profit-$4.60 million, earnings per share-$0.12Gross profit-$41000.00, with a price-to-earnings ratio of-1.94.

In terms of agency rating, there is currently no agency to make "buy, hold, sell" recommendations on the stock.

Vaccinex Inc shares rose 3.25% in the biotech industry as a whole. Among its related stocks, Biocardia Inc C/Wts 06 + 08 / To Pur Com, Mereo Biopharma Group Plc and Nls Pharmaceutics Ltd C/Wts 25 / 09 / To Pur Com rose a lot, while Kazia Therapeutics Limited, Mereo Biopharma Group Plc and Comera Life Sciences Holdings Inc were more active, with turnover rates of 87.78%, 71.89% and 51.69%, respectively. The related stocks with larger amplitudes are Biocardia Inc C/Wts 06, 08, and 2024 (To Pur Com), Tc Biopharm (Holdings), Plc C/Wts 08and02, and Sab Biotherapeutics Inc C/Wts 22, with amplitudes of 63.45%, 48.40%, and 40.10%, respectively.

About Vaccinex Inc: Vaccinex Inc is a biotech company in the clinical stage. The company is engaged in the discovery and development of targeted biotherapeutic drugs to treat serious diseases and symptoms with unmet medical needs, including cancer, neurodegenerative and autoimmune diseases. The company's product lines include pepinemab (VX15) for Huntington's disease (HD) and non-small cell lung cancer (NSCLC), as well as neurodegenerative diseases; VX5 Autoimmune for the treatment of multiple sclerosis and possibly other autoimmune diseases; and others.

(the above content is completed by Money Call, a self-selected intelligent machine writer, and is only used as a reference for users to look at the market, not as a basis for transaction. )